Literature DB >> 3690804

Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.

P A Speth1, P C Linssen, J B Boezeman, H M Wessels, C Haanen.   

Abstract

The effect of the duration of daunomycin (DNM) infusion on leukemic cell drug concentrations was evaluated. Cellular and plasma DNM concentrations were measured in 20 patients with acute non-lymphocytic leukemia. DNM 45 mg/m2 was administered either as a bolus injection or as a 4-, 8- or 72-h constant-rate infusion during 3 consecutive days. Peak plasma DNM levels amounted to 227 +/- 116 ng/ml after bolus injection and were only 16 +/- 6 ng/ml after 72-h DNM infusions. Terminal plasma DNM half-lives were 14 +/- 4 h. Peak leukemic cell DNM concentrations at the 3rd day of administration were 16810 +/- 2580 ng/10(9) cells (bolus injections) and 10310 +/- 5510 ng/10(9) cells (72-h infusions). The areas under the cellular curve were similar and independent of the duration of the DNM infusion. Peak leukemic cell daunomycinol (DNMol) concentrations were respectively 3500 +/- 1600 ng/10(9) cells and 2850 +/- 1720 ng/10(9) cells. Cellular DNM terminal half-life was 13 +/- 4 h. DNM concentrations in nucleated blood and bone marrow cells correlated well (r = 0.93, n = 26). Long-term infusion produced less severe side effects. Therapeutic efficacy was maintained during long-term infusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3690804     DOI: 10.1007/bf00262582

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Rapid quantitative determination of four anthracyclines and their main metabolites in human nucleated haematopoietic cells.

Authors:  P A Speth; P C Linssen; J B Boezeman; J M Wessels; C Haanen
Journal:  J Chromatogr       Date:  1986-04-25

2.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

3.  Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin.

Authors:  B Andersson; M Beran; C Peterson; B Tribukait
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

4.  Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.

Authors:  V Trillet; M Lakhal; J Lang; E Perrin-Fayolle; Q Timour Chah; D Fière; G Faucon
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia.

Authors:  J P Lewis; F J Meyers; L Tanaka
Journal:  Br J Haematol       Date:  1985-10       Impact factor: 6.998

6.  Experimental evaluation of anthracycline analogs.

Authors:  A M Casazza
Journal:  Cancer Treat Rep       Date:  1979-05

7.  Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.

Authors:  D D Von Hoff; M Rozencweig; M Layard; M Slavik; F M Muggia
Journal:  Am J Med       Date:  1977-02       Impact factor: 4.965

8.  Kinetics and sensitivity of daunorubicin in patients with acute leukemia.

Authors:  M W DeGregorio; W M Holleran; B A Macher; C A Linker; J R Wilbur
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cytometry       Date:  1985-03

10.  Effect of dose fractionation of daunorubicin on survival of leukemic cells.

Authors:  A Razek; F Valeriote; T Vietti
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

View more
  15 in total

1.  Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.

Authors:  T Dine; J C Cazin; B Gressier; M Luyckx; C Brunet; M Cazin; F Goudaliez; M L Mallevais; I Toraub
Journal:  Pharm Weekbl Sci       Date:  1992-12-11

2.  Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.

Authors:  Alex Bogason; Angelica L Quartino; Pierre Lafolie; Michèle Masquelier; Mats O Karlsson; Christer Paul; Astrid Gruber; Sigurd Vitols
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

3.  Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome.

Authors:  Kristin A D Sauter; Lisa J Wood; John Wong; Mihail Iordanov; Bruce E Magun
Journal:  Cancer Biol Ther       Date:  2011-06-15       Impact factor: 4.742

4.  Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis.

Authors:  J P Jaffrézou; T Levade; A Bettaïeb; N Andrieu; C Bezombes; N Maestre; S Vermeersch; A Rousse; G Laurent
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

Review 5.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.

Authors:  C Muller; E Chatelut; V Gualano; M De Forni; F Huguet; M Attal; P Canal; G Laurent
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Authors:  Federico Pea; Domenico Russo; Mariagrazia Michieli; Daniela Damiani; Renato Fanin; Angela Michelutti; Teresa Michelutti; Stefano Piccolrovazzi; Michele Baccarani; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.

Authors:  Alex Bogason; Hasanuzzaman Bhuiyan; Michèle Masquelier; Christer Paul; Astrid Gruber; Sigurd Vitols
Journal:  Eur J Clin Pharmacol       Date:  2009-10-10       Impact factor: 2.953

9.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.

Authors:  Savitha Varatharajan; Ajay Abraham; Wei Zhang; R V Shaji; Rayaz Ahmed; Aby Abraham; Biju George; Alok Srivastava; Mammen Chandy; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Eur J Clin Pharmacol       Date:  2012-05-05       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.